{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-006141","form_type":"8-K","ticker":"PLSE","cik":"0001625101","company_name":"PULSE BIOSCIENCES, INC.","filed_at":"2026-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.671889+00:00","generated_at":"2026-05-15T23:04:48.622605+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Pulse Biosciences CCO Kevin Danahy resigns effective immediately","bullets":["Kevin P. Danahy resigned as Chief Commercial Officer on February 27, 2026.","Resignation effective immediately, not due to any disagreement with the company.","Danahy was key to early commercialization efforts; company wishes him well.","No replacement named; CEO Paul LaViolette signed the filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-006141","json":"https://secwatch.observer/filing/0001437749-26-006141.json","markdown":"https://secwatch.observer/filing/0001437749-26-006141.md","text":"https://secwatch.observer/filing/0001437749-26-006141.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1625101/000143774926006141/0001437749-26-006141-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1625101/000143774926006141/plse20260226_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T23:04:48.622605+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}